Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2.
Tumati S, Herrmann N, Perin J, Rosenberg P, Lerner A, Mintzer J, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Shade D, Lanctôt K. Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2. International Psychogeriatrics 2024, 1-13. PMID: 39297292, DOI: 10.1017/s1041610224000711.Peer-Reviewed Original ResearchDementia Apathy Interview and RatingMinimal clinically important differenceDistribution-based analysisMeasure clinically relevant changesClinically important differenceClinically significant apathyAnchor-based analysesDementia careGlobal Impression of ChangeImpression of ChangeLinear mixed modelsAlzheimer's diseaseClinically relevant changesMMSE scoreImportant differenceApathy symptomsApathy ScaleControlled trialsSignificant apathyAnchor measuresDementiaStudy visitsApathy severityMethylphenidate trialSymptom severitySynaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 42. PMID: 38402233, PMCID: PMC10894197, DOI: 10.1038/s41531-024-00655-9.Peer-Reviewed Original ResearchSynaptic density lossPositron emission tomographyBinds to synaptic vesicle glycoprotein 2AAssociated with symptom severityParkinson's diseaseHigh-resolution positron emission tomographySynaptic vesicle glycoprotein 2ADuration of illnessPositron emission tomography scanBrain perfusionIllness durationSymptom severitySeverity of symptomsHC groupSubstantia nigraSynaptic densityLiving brainPD individualsClinical insightsDensity lossPD patientsEmission tomographyBrainSynaptic lossSynapse loss